By Canatu
Electrochemical biosensors using Canatu CNT provide >10-fold increased sensitivity in preliminary research in vitro matrices (internal, unpublished data). Exceptional sensitivity unlocks unpresented detection capabilities for new assays. Electrochemical biosensor concepts utilizing Canatu carbon nanotube (CNT) technology have demonstrated a >10-fold higher sensitivity in preliminary research in vitro matrices (internal, unpublished data). Superior sensitivity is made possible by our patented dry deposition technology yielding the most advanced CNTs with incredibly extensive and pristine reaction surface area. This enormous, three-dimensional surface provides many binding sites for biorecognition elements to interact with target analytes, enabling stronger signals even in complex matrices. Exceptional sensitivity unlocks unprecedented detection capabilities for new assays. Furthermore, this technology platform is being developed with the goal to detect severe infections and diseases, such as cancer, at early stages. Key benefits - Sensitive: Demonstrated >10x higher sensitivity in research-stage in vitro matrices (internal, unpublished data) - Versatile: An adaptable platform technology customizable for target analytes of interest - At scale: Leveraging our proven industrial expertise to scale future medical sensor production to tens of millions of units annually Exceptional sensitivity Canatu’s proprietary CNT sensing technology has demonstrated over 10x increased sensitivity in preliminary research in vitro matrices (internal, unpublished data), highlighting its potential for detecting low-concentration analytes. It has been achieved through our patented dry deposition technology, which allows us to produce carbon nanotubes with uniquely large and pristine reaction surfaces. Versatile platform technology Our proprietary click chemistry enables the immobilization of any biorecognition element, including antibodies, DNAs, enzymes, and aptamers, making it a highly adaptable platform technology optimized for various target analytes of interest. In research environments, Canatu technology has shown potential for early-stage cancer investigation by detecting low concentrations of circulating tumor DNA from small model samples. At scale Canatu has established infrastructure and expertise to scale manufacturing to tens of millions of components annually. While we have successfully mass-produced carbon nanotube products and sensors for highly demanding industries like automotive since 2015, we are preparing to bring this established industrial scalability to the medical diagnostics market under applicable quality standards. Our patented dry deposition method and electrode patterning process are fully compatible with roll-to-roll production and have been successfully demonstrated at an industrial scale. Lab on a chip Simultaneous testing of multiple biomarkers from a single sample is a core objective of our development platform. These analytes can include DNA mutations, pathogens, hormones, and drug molecules. These microfluidic chips will offer high sensitivity, portability, and the capability to perform complex analyses with minimal sample consumption. Multiplex assays can be customized at any sensor design to recognize different target analytes with the same sample. Versatile platform technology for detecting any analyte of interest Canatu’s proprietary click chemistry enables the immobilization of biorecognition elements, including antibodies, DNAs, enzymes, and aptamers, making it a versatile platform technology for detecting any analyte of interest, such as pathogens, hormones, DNA mutations, and drug molecules. Canatu has, for example, demonstrated pre-metastatic cancer detection by analyzing circulating tumor DNA from extremely small blood samples right at the point-of-care. Multiple disease-specific biomarkers can be tested simultaneously from a small blood sample, enabling rapid results and better patient care. Exceptionally sensitive electrochemical biosensors Electrochemical biosensor functions by converting biochemical events into electrical signals. At its core is the electrode, providing stable support for immobilizing biomolecules and facilitating electron movement. Carbon nanotubes stand out as ideal electrodes, thanks to their large and pristine surface area, providing many binding sites for the analytes. Electrochemical biosensor concepts using Canatu CNT demonstrated over 10x increased sensitivity in preliminary research in vitro matrices (internal, unpublished data). This heightened sensitivity is made possible through our patented dry deposition technology, which produces CNTs with exceptionally pristine and large surface areas. To illustrate this, just one gram of Canatu CNTs boasts a surface area equivalent to that of a soccer field. Large surface provides many binding sites for biorecognition elements to attach with the target analytes. Moreover, the unique three-dimensional carbon structure of CNTs enables robust and reliable attachment of biorecognition elements, resulting in stronger signals even within complex matrices. Unprecedented sensitivity enables new assays and allows for the early detection of severe diseases and infections, even before their onset. Our patented click chemistry provides a versatile platform technology for detecting any analyte of interest, including DNA mutations, pathogens, hormones, and drug molecules, offering a unique opportunity to diagnose severe diseases, like cancer, or infections at their earliest stages, saving lives and money. Employing biorecognition elements like DNAs, antibodies, aptamers, and enzymes, click chemistry immobilizes electrodes to specific target analytes, generating electrical signals processed by an electronic system. The inherently large specific surface area, high electrical conductivity, and tailorable surface chemistry make Canatu CNT an ideal electrode for electrochemical biosensors, offering industry-leading sensitivity. Electrochemical biosensors for detecting painkiller concentrations Canatu has collaborated with leading Finnish universities and Helsinki University Hospital to develop electrode strips for point-of-care measurements of painkiller concentrations. In this partnership, test strips capable of quantitatively detecting painkillers, including paracetamol and opioids, have been created. Given the widespread misuse of these medications, they are common causes of poisoning. The feasibility of these prototype test strips has been evaluated in three early-stage, exploratory clinical research studies, including an initial proof-of-concept study measuring paracetamol (acetaminophen) concentrations. The developed test strips utilize the highly sensitive and repeatable Canatu CNT electrode platform, ensuring a high signal-to-noise ratio. Regulatory Status Notice: Canatu’s electrochemical biosensor solutions for medical diagnostics are currently in the concept and feasibility development phase. These technology concepts, components, and provisional specifications are intended exclusively for research, evaluation, and co-development partnership purposes. They are not cleared or approved by any regulatory authority for clinical diagnostic use, nor are they commercially available as medical devices. All technical parameters are provisional and subject to verification within design control phases.
